Avecho completes recruitment for Phase III interim analysis

Melbourne, Australia, 2 March 2026: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or “the Company”) is pleased to announce the completion of recruitment for the interim analysis cohort of participants for its pivotal Phase III clinical trial evaluating its TPM®-enhanced cannabidiol (CBD) capsule for insomnia. The Company has successfully enrolled the approximately 210 participants required for